Company intelligence / Profile preview
Orchard Therapeutics
London, United Kingdomorchard-tx.com ↗
- Ownership
- Public · ORTX
- Employees
- ~222
- Development stage
- Other
01
Overview
Orchard Therapeutics has developed Libmeldy (OTL-200) for MLD which is approved in Europe, with a pending BLA in the US. The company has treated more than 160 patients across six different disease areas with up to 10 years of post-treatment follow-up in some conditions.
- Therapeutic areas
- HematologyImmunologyRare DiseasesNeurology
- Modalities
- Ex vivo autologous hematopoietic stem cell (HSC) gene therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
GSK (acquired GSK's rare disease gene therapy portfolio in 2018)San Raffaele Telethon Institute for Gene Therapy
Beyond the preview
Go deeper on Orchard Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orchard Therapeutics.